NPCE

In May 2026, NeuroPace reported Q1 2026 financial results with $22.1 million in revenue and 19.5% year-over-year RNS System revenue growth, raising its full-year 2026 revenue guidance to $99-$101 million. In August 2026, Q2 2026 revenue was $22.8 million, up 17% year-over-year, with RNS System revenue increasing by 21.3%, leading to another raise in 2026 revenue guidance to $99.5-$101.5 million and improved Adjusted EBITDA guidance. Regulatory and product developments included FDA approval of its ECoG Assistant™ in May 2026 and FDA guidance in July 2026 for a PMA Supplement for indication expansion into Idiopathic Generalized Epilepsy. The company also highlighted expanding clinical evidence with published 3-year Post-Approval Study results and NAUTILUS presentation data at AAN 2026, showing significant seizure reduction. NeuroPace participated in the 2026 Cantor Global Healthcare Conference and the Wells Fargo 21st Annual Healthcare Conference in September and August 2026, respectively. As of early October 2026, NPCE shares experienced volatility, with a 52-week range of $9.22 to $19.60, declining by 3.4% on October 2, 2026, 16.4% over the past month, and 17.8% year-to-date. Insider selling of $0.4 million over the past 12 months, with no buying activity, was noted as a potential negative signal.